Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of Global Cord Blood (NYSE:CO – Free Report) in a research note issued to investors on Thursday. The brokerage issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Stock Performance

Shares of Global Cord Blood stock opened at $2.99 on Thursday. Global Cord Blood has a 52 week low of $2.03 and a 52 week high of $5.50. The stock has a 50 day moving average price of $1.48 and a two-hundred day moving average price of $1.34. The stock has a market capitalization of $363.44 million, a PE ratio of 2.34 and a beta of 0.16.

Global Cord Blood Company Profile

(Get Free Report)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.

Featured Articles